761299AB2
Retrophin Inc
Could not find a ticker for this position, may be a filing error
A biopharmaceutical company that develops and sells medicines for rare kidney, liver, and metabolic diseases, including the kidney drug FILSPARI and the legacy products Thiola and Thiola EC. It was founded in 2011 by Martin Shkreli, who coined the name "Retrophin" as a mash-up of "replace dystrophin," reflecting its original goal of treating Duchenne muscular dystrophy. In 2020 the company rebranded as Travere Therapeutics to shed its association with its founder.
CONVERTIBLEUnderlying: RTRXCUSIP: 761299AB2HealthcareUS1 derivative reporter
2.5% Convertible Senior Notes due September 15, 2025
No tracked superinvestor held this security as stock in this period — only the derivative positions below reference it.
Derivative Reporters
Investor
Kind
13F reported value
Quantity
Change
